In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. [electronic resource]
Producer: 20110222Description: 6101-5 p. digitalISSN:- 1528-0020
- Adolescent
- Adult
- Age Factors
- Anticoagulants -- administration & dosage
- Aryl Hydrocarbon Hydroxylases -- genetics
- Child
- Child, Preschool
- Cohort Studies
- Cytochrome P-450 CYP2C9
- Genotype
- Humans
- Infant
- Infant, Newborn
- Mixed Function Oxygenases -- genetics
- Phenprocoumon -- administration & dosage
- Polymorphism, Genetic -- genetics
- Prognosis
- Prospective Studies
- Thrombosis -- drug therapy
- Vitamin K -- antagonists & inhibitors
- Vitamin K Epoxide Reductases
- Warfarin -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.